MASS
908 Devices Inc.·Healthcare
8.16
3.030%(+0.24)
Close PriceLast Updated: — ET
52W L: $5.0352W H: $9.34
MASS NEWS
seekingalpha.com
May 18
908 Devices Looking Better Now (Rating Upgrade)
908 Devices (MASS) delivered strong Q1 results, raising full-year revenue guidance after a strategic acquisition in narcotics detection. Adjusted gross margins improved nearly three percentage points to 57%, and operating cash flow turned positive. The company has a solid balance sheet with nearly $100 million in cash post-acquisition and is debt free, while trading at a reasonable valuation.
seekingalpha.com
May 6
908 Devices Inc. (MASS) Q1 2026 Earnings Call Transcript
908 Devices Inc. (MASS) Q1 2026 Earnings Call Transcript
zacks.com
May 6
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.15 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.22 per share a year ago.
businesswire.com
May 6
908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)-- #ChemicalID--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. “We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are also excited to announce the acquisition of NIRLAB AG, a strate.
businesswire.com
May 6
908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio
BURLINGTON, Mass.--(BUSINESS WIRE)-- #LawEnforcement--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared (NIR) spectroscopy to perform handheld chemical analysis of narcotics in seconds. This acquisition expands 908 Devices' analytical portfolio and strengthens its leadership in narcot.
businesswire.com
May 1
908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the first quarter 2026 before market open on Wednesday, May 6, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” sect.
